Barrett’s Esophagus Treatment Market: Changes in Lifestyle Leading to Obesity Benefits Market, finds TMR

A recently added report by Transparency Market Research, titled, “Barrett’s Esophagus Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025,” studies the scope for players offering therapy of Barrett’s Esophagus. Barrett’s Esophagus, resulting from gastro-esophageal reflux disease (GERD) in which the normal squamous tissue lining the esophagus transforms into that lining the intestine. More than 10% of people with GERD get Barrett’s esophagus. And a rare less than one percent of Barrett’s patients develop cancer of the esophagus.

The biggest threat from Barrett’s Esophagus is that it remains mostly undiagnosed. This, however, also means ample of room for players in the market to grow. Changes in lifestyle resulting in obesity and growing consumption of alcohol, which causes GERD among people, leading to Barrett’s esophagus is expected to contribute to the growth of the market. However, the asymptomatic condition of Barrett’s esophagus, patent expiry of drugs employed for the treatment of GERD, and the availability of over-the counter drugs might hamper future market growth.

The three types of Barrett’s esophagus are intestinal metaplasia without dysplasia; high-grade dysplasia; and low-grade dysplasia. The treatment centers on the extent of dysplasia in the esophageal cells and usually entails medications and surgeries. Some of the medications are proton pump inhibitors, H2 blockers, promotility agents, antacids, and others. Surgical therapies entail radiofrequency ablation, endoscopic spray cryotherapy, photodynamic therapy, endoscopic mucosal resection, and surgery.

Geographically, North America accounts for maximum share in Barrett’s esophagus treatment market because of the considerable prevalence of the disease and initiatives by organizations to generate awareness among people.

Key players in Barrett’s esophageal treatment market are AstraZeneca, Plc., Addex Therapeutics, Rottapharm (Meda AB), Takeda Pharmaceutical Company Limited, Mederi Therapeutics, Eisai Co. Ltd., Pfizer, Inc., Torax Medical, Torax Medical, Inc., Aros Pharma, and C. R. Bard.

To Get a Brochure @

Leave a Reply